Skip to main content

Advertisement

Table 1 Average patient and disease characteristics for all included visits with Disease Activity Score ≤ 2.4 but > 1.6

From: Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning

  No treatment intensification Treatment intensification
Age, years, mean (SD) 52.6 (12.6) 51.0 (12.4)
Sex, n (% female) 46 (78.9) 39 (68.4)
Treatment arm
 Early remission 46.2 57.2
 MTX + SSZ + HCQ + prednisone 20.9 19.9
 MTX + adalimumab 19.1 16.0
 Out of protocol 13.8 6.7
Symptom duration, weeks, median (IQR) 20 (9–35) 19 (9–32)
Diagnosed RA, % meeting 2010 ACR/EULAR criteria 46 (79.2) 47 (84.5)
Anti-citrullinated protein antibodies, % positive 34 (57.6) 35 (61.9)
Rheumatoid factor, % positive 33 (58.9) 34 (63.0)
Health Assessment Questionnaire (0–3)a, mean (SD) 0.78 (0.56) 0.63 (0.48)
Disease Activity Score, mean (SD) 1.95 (0.23) 1.99 (0.23)
Tender joint count, median (IQR) 2 (2–4) 3 (2–4)
Swollen joint count, median (IQR) 0 (0–1) 1 (0–2)
VAS general health (0–100)b, mean (SD) 31.0 (19.6) 31.7 (20.3)
Erythrocyte sedimentation rate, mm/h, median (IQR) 15.7 (13.0) 13.9 (11.2)
  1. Abbreviations: ACR/EULAR American College of Rheumatology/European League Against Rheumatism, RA Rheumatoid arthritis, VAS Visual analogue scale, MTX Methotrexate, SSZ Sulphasalazine, HCQ Hydroxychloroquine
  2. The average number of patients per visit with low disease activity without a treatment intensification was 56 (range 24–103), and the average number of patients per visit with low disease activity with treatment intensification was 61 (range 30–77)
  3. a0 = No functional limitations
  4. b100 = Best score